These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 31681587)

  • 1. Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers.
    Arner EN; Du W; Brekken RA
    Front Oncol; 2019; 9():1049. PubMed ID: 31681587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy.
    Sun NY; Yang MH
    Front Oncol; 2020; 10():792. PubMed ID: 32509584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis.
    Yoon C; Till J; Cho SJ; Chang KK; Lin JX; Huang CM; Ryeom S; Yoon SS
    Mol Cancer Res; 2019 Sep; 17(9):1945-1957. PubMed ID: 31217166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer.
    Kim RK; Suh Y; Lim EJ; Yoo KC; Lee GH; Cui YH; Son A; Hwang E; Uddin N; Yi JM; Kang SG; Lee SJ
    Cancer Lett; 2013 Aug; 337(1):49-57. PubMed ID: 23707634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer.
    Zhong X; Zheng L; Shen J; Zhang D; Xiong M; Zhang Y; He X; Tanyi JL; Yang F; Montone KT; Chen X; Xu C; Xiang AP; Huang Q; Xu X; Zhang L
    Mol Cell Biol; 2016 Nov; 36(21):2742-2754. PubMed ID: 27550813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics.
    Smigiel JM; Parameswaran N; Jackson MW
    Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29320425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Mutation of
    Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
    Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
    Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
    Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.
    Drak Alsibai K; Meseure D
    Dev Dyn; 2018 Mar; 247(3):405-431. PubMed ID: 28691356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic reprogram associated with epithelial-mesenchymal transition in tumor progression and metastasis.
    Wang Y; Dong C; Zhou BP
    Genes Dis; 2020 Jun; 7(2):172-184. PubMed ID: 32215287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers.
    Adachi Y; Kimura R; Hirade K; Ebi H
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMT Transition States during Tumor Progression and Metastasis.
    Pastushenko I; Blanpain C
    Trends Cell Biol; 2019 Mar; 29(3):212-226. PubMed ID: 30594349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell Heterogeneity and Phenotypic Plasticity in Metastasis Formation: The Case of Colon Cancer.
    Teeuwssen M; Fodde R
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Plasticity and Epithelial-Mesenchymal Transition.
    Thomson TM; Balcells C; Cascante M
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31277295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition in development and cancer.
    Micalizzi DS; Ford HL
    Future Oncol; 2009 Oct; 5(8):1129-43. PubMed ID: 19852726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
    Bhatia S; Wang P; Toh A; Thompson EW
    Front Mol Biosci; 2020; 7():71. PubMed ID: 32391381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.
    Malek R; Wang H; Taparra K; Tran PT
    Cells Tissues Organs; 2017; 203(2):114-127. PubMed ID: 28214899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
    Nouri M; Ratther E; Stylianou N; Nelson CC; Hollier BG; Williams ED
    Front Oncol; 2014; 4():370. PubMed ID: 25566507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.